Thomas Delate

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5521099/publications.pdf

Version: 2024-02-01

82 papers 1,833 citations

394421 19 h-index 276875 41 g-index

82 all docs 82 docs citations

82 times ranked 2933 citing authors

#	Article	IF	Citations
1	Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. Journal of the National Cancer Institute, 2012, 104, 1293-1305.	6.3	469
2	Risk of Thromboembolism, Recurrent Hemorrhage, and Death After Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding. Archives of Internal Medicine, 2012, 172, 1484.	3.8	202
3	Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood, 2009, 114, 952-956.	1.4	111
4	Bleeding, Recurrent Venous Thromboembolism, and Mortality Risks During Warfarin Interruption for Invasive Procedures. JAMA Internal Medicine, 2015, 175, 1163.	5.1	92
5	Clinical Outcomes of a Homeâ€Based Medication Reconciliation Program After Discharge from a Skilled Nursing Facility. Pharmacotherapy, 2008, 28, 444-452.	2.6	60
6	Outpatient Use of Low Molecular Weight Heparin Monotherapy for First-Line Treatment of Venous Thromboembolism in Advanced Cancer. Oncologist, 2012, 17, 419-427.	3.7	46
7	Warfarin Interactions With Antibiotics in the Ambulatory Care Setting. JAMA Internal Medicine, 2014, 174, 409.	5.1	44
8	Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study. Pharmacotherapy, 2008, 28, 960-967.	2.6	40
9	Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer, 2012, 78, 245-252.	2.0	40
10	Mortality Reduction Benefits of a Comprehensive Cardiac Care Program for Patients with Occlusive Coronary Artery Disease. Pharmacotherapy, 2007, 27, 1370-1378.	2.6	38
11	Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thrombosis Research, 2013, 132, 770-775.	1.7	37
12	Validation of Electronic Data on Chemotherapy and Hormone Therapy Use in HMOs. Medical Care, 2013, 51, e67-e73.	2.4	34
13	Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thrombosis Research, 2015, 136, 1040-1044.	1.7	29
14	Assessment of the coding accuracy of warfarin-related bleeding events. Thrombosis Research, 2017, 159, 86-90.	1.7	29
15	Metabolic Monitoring in Commercially Insured Pediatric Patients Newly Initiated to Take a Second-Generation Antipsychotic. JAMA Pediatrics, 2014, 168, 679.	6.2	25
16	Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 189-197.e3.	2.6	25
17	<i>KRAS</i> Testing and Epidermal Growth Factor Receptor Inhibitor Treatment for Colorectal Cancer in Community Settings. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 91-101.	2,5	24
18	Medication strategies used by Medicare beneficiaries who reach the Part D standard drug-benefit threshold. American Journal of Health-System Pharmacy, 2008, 65, 1062-1070.	1.0	22

#	Article	IF	Citations
19	Methadone for Pain and the Risk of Adverse Cardiac Outcomes. Journal of Pain and Symptom Management, 2014, 48, 333-342.e1.	1.2	21
20	Impact of a clinical pharmacy research team on pharmacy resident research. American Journal of Health-System Pharmacy, 2015, 72, 309-316.	1.0	20
21	Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting. Open Forum Infectious Diseases, 2020, 7, ofaa034.	0.9	20
22	Validity of Eight Integrated Healthcare Delivery Organizations' Administrative Clinical Data to Capture Breast Cancer Chemotherapy Exposure. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 673-680.	2.5	19
23	Falsely Elevated International Normalized Ratio Values in Patients Undergoing Anticoagulation Therapy. Chest, 2007, 131, 816-822.	0.8	18
24	Thrombophilia testing patterns amongst patients with acute venous thromboembolism. Thrombosis Research, 2015, 136, 1160-1164.	1.7	18
25	Positive predictive values of ICD-9 codes to identify patients with stroke or TIA. American Journal of Managed Care, 2014, 20, e27-34.	1.1	17
26	Indications for Rituximab Use in an Integrated Health Care Delivery System. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 832-838.	0.9	16
27	Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003ââ,¬â€œ2008: The Effect of the NCI Clinical Recommendation. Frontiers in Oncology, 2014, 4, 43.	2.8	15
28	Effectiveness of a Clinical Pharmacist Medication Therapy Management Program in Discontinuation of Drugs to Avoid in the Elderly. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 525-531.	0.9	14
29	Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience. Journal of Thoracic Oncology, 2014, 9, 692-701.	1.1	13
30	Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2010, 29, 316-321.	2.1	12
31	Empiric warfarin dose adjustment with prednisone therapy. A randomized, controlled trial. Journal of Thrombosis and Thrombolysis, 2011, 31, 472-477.	2.1	11
32	Effect of increased time in the therapeutic range on atrial fibrillation outcomes within a centralized anticoagulation service. Thrombosis Research, 2018, 163, 54-59.	1.7	11
33	Adherence to and persistence with direct oral anticoagulant therapy among patients with new onset venous thromboembolism receiving extended anticoagulant therapy and followed by a centralized anticoagulation service. Thrombosis Research, 2020, 193, 40-44.	1.7	11
34	Reduced Health Care Expenditures After Enrollment in a Collaborative Cardiac Care Service. Pharmacotherapy, 2010, 30, 1127-1135.	2.6	10
35	An Education Program for Patient Self-Management of Warfarin. , 2015, 19, 33-8.		10
36	The Sustainability of Improvements from Continuing Professional Development in Pharmacy Practice and Learning Behaviors. American Journal of Pharmaceutical Education, 2015, 79, 36.	2.1	10

3

#	Article	IF	CITATIONS
37	Evaluation of venous thromboembolism risk following hospitalization. Journal of Thrombosis and Thrombolysis, 2011, 32, 32-39.	2.1	9
38	Impact of a Clinical Pharmacy Specialist in an Emergency Department for Seniors. Annals of Emergency Medicine, 2016, 67, 177-188.	0.6	9
39	Pharmacy Survey on Patient Safety Culture: Benchmarking Results. Journal of Patient Safety, 2017, 13, 37-42.	1.7	9
40	Patient Perspectives on Switching from Infliximab to Infliximabâ€dyyb in Patients with Rheumatologic Diseases in the United States. ACR Open Rheumatology, 2019, 1, 52-57.	2.1	9
41	Metabolic monitoring in children 5 years of age and younger prescribed second-generation antipsychotic medications. Mental Health Clinician, 2017, 7, 1-6.	1.0	9
42	Clinical outcomes of dabigatran use in patients with non-valvular atrial fibrillation and weight >120Âkg. Thrombosis Research, 2021, 208, 176-180.	1.7	9
43	Pilot Study of a Novel Patient Selfâ€Management Program for Warfarin Therapy Using Venipunctureâ€Acquired International Normalized Ratio Monitoring. Pharmacotherapy, 2012, 32, 1078-1084.	2.6	8
44	Ambulatory Clinical Pharmacy Specialty Services: The Kaiser Permanente Colorado Experience. Journal of Managed Care Pharmacy, 2014, 20, 245-253.	2.2	8
45	Cluster-Randomized Trial of Clinical Pharmacist Tobacco Cessation Counseling Among Patients with Cardiovascular Disease. Population Health Management, 2015, 18, 300-306.	1.7	8
46	Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. Thrombosis Research, 2016, 137, 97-102.	1.7	8
47	Bridge Therapy Outcomes in Patients With Mechanical Heart Valves. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 1036-1041.	1.7	8
48	Out-of-Plan Pharmacy Use by Members of a Managed Care Organization., 2012, 16, 15-21.		8
49	A descriptive evaluation of warfarin use in patients receiving hospice or palliative care services. Journal of Thrombosis and Thrombolysis, 2009, 27, 334-339.	2.1	7
50	Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol. BMJ Open, 2015, 5, e009518.	1.9	7
51	Renal Drug Dosing. Applied Clinical Informatics, 2016, 07, 731-744.	1.7	7
52	A Randomized Controlled Trial of Empiric Warfarin Dose Reduction with the Initiation of Doxycycline Therapy. Thrombosis Research, 2012, 130, 152-156.	1.7	6
53	Thromboembolic and Bleeding Outcomes of Extended Duration Low-Intensity Warfarin Following Elective Total Knee Arthroplasty. Thrombosis Research, 2015, 135, 267-271.	1.7	6
54	Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharmacy Practice, 2017, 15, 946-946.	1.5	6

#	Article	IF	Citations
55	Temporal trends in first-line outpatient anticoagulation treatment for cancer-associated venous thromboembolism. Thrombosis Research, 2020, 196, 367-370.	1.7	6
56	Validation of algorithms to identify elective percutaneous coronary interventions in administrative databases. PLoS ONE, 2020, 15, e0231100.	2.5	6
57	Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample. PLoS ONE, 2014, 9, e94977.	2.5	6
58	Birth outcomes with prescribed chronic and acute opioid exposure during pregnancy. Journal of Opioid Management, 2019, 15, 407-415.	0.5	5
59	Effect of Patient Notification of Formulary Change on Formulary Adherence. Journal of Managed Care Pharmacy, 2005, 11, 493-498.	2.2	4
60	Vitamin K versus warfarin interruption alone in patients without bleeding and an international normalized ratio > 10. Journal of Thrombosis and Haemostasis, 2020, 18, 1133-1140.	3.8	4
61	An evaluation of a clinical pharmacy-directed intervention on blood pressure control. Pharmacy Practice, 2006, 4, 110-6.	1.5	4
62	Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma. Journal of Asthma, 2017, 54, 105-110.	1.7	3
63	Can We Predict Individual Combined Benefit and Harm of Therapy? Warfarin Therapy for Atrial Fibrillation as a Test Case. PLoS ONE, 2016, 11, e0160713.	2.5	3
64	Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting. Pharmacy Practice, 2009, 7, 205-12.	1.5	3
65	Effectiveness of Best Practice Alerts for Potentially Inappropriate Medication Orders in Older Adults in the Ambulatory Setting. , 2020, 24, .		3
66	Universal hepatitis B screening and management in patients with cancer who received immunosuppressive chemotherapy. Journal of Oncology Pharmacy Practice, 2020, 26, 1141-1146.	0.9	2
67	Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections. BMC Infectious Diseases, 2021, 21, 823.	2.9	2
68	A Predictive Model to Identify Skilled Nursing Facility Residents for Pharmacist Intervention. The Consultant Pharmacist, 2018, 33, 504-520.	0.4	1
69	Trends in high intensity statin use among secondary prevention patients 76 years and older. Pharmacy Practice, 2019, 17, 1402.	1.5	1
70	Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy. Personalized Medicine, 2020, 17, 185-194.	1.5	1
71	Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use. Family Practice, 2021, 38, 623-629.	1.9	1
72	Clinical Effectiveness of an Outpatient Multidisciplinary Chronic Pain Management Telementoring Service. Clinical Journal of Pain, 2021, 37, 740-746.	1.9	1

#	Article	IF	CITATIONS
73	Analysis Of Warfarin Drug-Drug Interactions With Antibiotics In The Ambulatory Care Setting. Blood, 2013, 122, 1143-1143.	1.4	1
74	Perceptions of the Value of Clinical Pharmacy Medication Review for Women During Early Pregnancy. Journal of Managed Care & Decialty Pharmacy, 2020, 26, 1301-1308.	0.9	1
75	Out-of-plan pharmacy use: insights into patient behavior. American Journal of Managed Care, 2014, 20, 995-1001.	1.1	1
76	Supratherapeutic International Normalized Ratios in Warfarin-Treated Patients Who Receive a Highly Potentiating Antimicrobial Course—Reply. JAMA Internal Medicine, 2014, 174, 1200.	5.1	0
77	Clinical Outcomes of Continuation of Metformin Titration Instructions with Electronic Prescribing. Drugs - Real World Outcomes, 2015, 2, 187-192.	1.6	O
78	In reply:. Annals of Emergency Medicine, 2016, 68, 393-394.	0.6	0
79	Assessment of the rates and characteristics of the short-term supply of medication (Tider) from an integrated healthcare delivery system in the United States. Pharmacy Practice, 2017, 15, 940-940.	1.5	O
80	Patterns of Care for Biologic-Dosing Outliers and Nonoutliers in Biologic-Naive Patients with Rheumatoid Arthritis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 798-808.	0.9	0
81	Assessment of Pharmacy Department Patient Safety Culture with the Use of Validated Work Environment Survey Indices., 2018, 22, 17-070.		0
82	Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small cell lung cancer Journal of Clinical Oncology, 2014, 32, 8069-8069.	1.6	O